Shiva Natarajan
Neurology · Germantown, TNNPI 1730132788
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $93,620 of the $139,353 with a category attached, or 67.2%. 60 manufacturers reported payments, led by SK Life Science, Inc. at 47.4% of the total. Among neurology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,777 payments — averaging $78.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SK Life Science, Inc.$66K
- Pfizer$22K
- Biohaven Pharmaceuticals, Inc.$14K
- Promius Pharma LLC$5K
- Biohaven Pharmaceutical Holding Company Ltd.$5K
- Novartis$3K
- plus $23K from 54 others
Across 2 payments — averaging $403.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$806
What the payments were for
- Consulting fees$5,5254%
- Speaking & faculty fees$93,62067%
- Travel & lodging$9,1217%
- Food & beverage$30,82922%
- Education$2580%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XCOPRI$51,474
- NURTEC ODT$25,171
- ZAVZPRET$14,519
- Cenobamate$11,594
- VNS Therapy$1,514
- APTIOM$1,243
- Assurity Pacemaker$145
- WATCHMAN Access System$122
- Briviact$121
- KESIMPTA$115
- BRILINTA$106
- Carto 3 System$102
How this compares
$139,353 in reported general payments places this provider in the 95th percentile of 361 neurology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 51 | $1,234,807 |
| UltomirisRavulizumab-Cwvz | 16 | $844,557 |
| Vyvgart HytruloEfgartigimod-Hyaluronidas-Qvfc | 14 | $682,087 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 35 | $485,052 |
| XcopriCenobamate | 367 | $475,304 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 24 | $452,696 |
| Kesimpta PenOfatumumab | 50 | $438,743 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 18 | $296,125 |
| AptiomEslicarbazepine Acetate | 93 | $248,104 |
| BriviactBrivaracetam | 158 | $248,059 |
| EpidiolexCannabidiol (Cbd) | 35 | $231,890 |
| NuplazidPimavanserin Tartrate | 32 | $169,292 |
| BetaseronInterferon Beta-1b | 11 | $124,875 |
| AubagioTeriflunomide | 12 | $110,351 |
| Nurtec OdtRimegepant Sulfate | 83 | $88,518 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam, Nurtec Odt | $22,429 | $1,323,325134 claims |
| AstraZenecaUltomiris | $1,705 | $844,55716 claims |
| Argenx US, Inc.Vyvgart Hytrulo | $826 | $682,08714 claims |
| SK Life Science, Inc.Xcopri | $66,104 | $475,304367 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid, Trintellix | $82 | $473,25965 claims |
| UCB, Inc.Briviact, Vimpat, Neupro, Nayzilam | $1,955 | $371,795269 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $1,925 | $248,10493 claims |
| Acadia Pharmaceuticals IncNuplazid | $810 | $169,29232 claims |
| AbbVieQulipta, Ubrelvy, Botox | $1,281 | $129,940103 claims |
| BayerBetaseron | $79 | $124,87511 claims |
| SanofiAubagio | $422 | $110,35112 claims |
| Ipsen Biopharmaceuticals, IncDysport | $157 | $59,05835 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 361 neurology providers in Tennessee.
Other neurology in Germantown
- Rance WilbournGermantown$52K
- Samuel HunterSpring Hill$676K
- Harold MosesNashville$438K
- Lucas ElijovichMemphis$415K
- David BrandesKnoxville$412K
- Sibyl WrayKnoxville$377K
- Christine HagenAlcoa$371K
- Mark LedouxMemphis$352K
- Christopher PendolaKingsport$344K
- Daniel ClaassenNashville$285K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.